Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697719 · ClinicalTrials.gov registry record · Phase 4
Body Weight, Aspirin Dose and Pro-resolving Mediators
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT04697719: Completed Phase 4 study, sponsored by NYU Langone Health.
NCT04697719 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 103 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04697719, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
Interventions
- DRUG Aspirin 325mg
- DRUG Aspirin 81mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2025-01-29 |
| Phase | Phase 4 |
What the finished NCT04697719 record still lists
NCT04697719 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Aspirin 325mg is the first listed.
NCT04697719 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04697719 about?
NCT04697719 is a clinical study titled "Body Weight, Aspirin Dose and Pro-resolving Mediators". This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
What is the current status of trial NCT04697719?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2021-11-04. Estimated completion is 2025-01-29.
What interventions are being tested in trial NCT04697719?
The interventions under investigation include: Aspirin 325mg (DRUG), Aspirin 81mg (DRUG).
Who is sponsoring clinical trial NCT04697719?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04697719's enrollment target sits among peer trials
103 760th of 2000 higher than 1,237 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI